Hormone Replacement Therapy Guidelines

Introduction to Hormone Replacement Therapy

Hormone replacement therapy (HRT) is used for menopause, management of estrogen-dependent conditions, and hormone therapy in transgender individuals, with the goal of using the lowest effective dose for the shortest duration consistent with treatment goals, as recommended by the American College of Oncology and other guidelines 1, 2, 3

HRT is contraindicated in patients with a history of breast cancer, estrogen-dependent neoplasia, and active thromboembolic disorders, and individual risk factors for thromboembolism and cardiovascular disease should be considered, according to the American Heart Association and other guidelines 3, 4
Estrogen-containing oral contraceptives are not recommended for patients at risk of thromboembolism, such as those with cyanosis related to intracardiac shunt, severe pulmonary arterial hypertension, or Fontan repair 4
Higher doses of estradiol may increase risks of stroke, gallbladder disease, and urinary incontinence, as stated in the guidelines for HRT 3

For contraception in women with chronic liver disease, combined hormonal contraception, progestin-only pills, and intrauterine devices are considered safe unless advanced cirrhosis is present, according to the European Association for the Study of the Liver 5
Natural micronized progesterone (100-200 mg daily) is preferred over synthetic progestins for balancing estrogen effects and may influence estradiol-estrone ratios, as recommended by the Annals of Oncology 1

Transdermal administration of estradiol is preferred for better estradiol:estrone ratios, and continuous (non-cyclic) estrogen therapy without breaks can be used, according to the guidelines for HRT 1
The recommended starting dose of estradiol for post-hysterectomy patients is 1-2 mg daily of oral estradiol or 50-100 micrograms of transdermal estradiol daily, with transdermal administration being the preferred route due to its superior safety profile, as stated in the guidelines for HRT 2
Transdermal estradiol is more effective for bone mineral density preservation and has a more beneficial effect on lipids, inflammation markers, and blood pressure, with a starting dose of 50-100 micrograms daily 2

Regular assessment of symptoms and consideration of periodic hormone level testing if clinically indicated is necessary for managing estradiol conversion, as recommended by the Annals of Oncology 1
Treatment should be reevaluated periodically (every 3-6 months) to determine if treatment is still necessary, with attempts to taper medication at 3-6 month intervals to determine if continued therapy is needed, according to the guidelines for HRT 2, 3
Aromatase inhibitors are often used but cause significant vaginal dryness, and local vaginal treatments may be considered with caution, with estriol-containing preparations being preferable to estradiol in these patients, as recommended by the Annals of Oncology 1